TY - JOUR
T1 - EASL Clinical Practice Guidelines
T2 - The diagnosis and management of patients with primary biliary cholangitis
AU - Hirschfield, Gideon M
AU - Beuers, Ulrich
AU - Corpechot, Christophe
AU - Invernizzi, Pietro
AU - Jones, David
AU - Marzioni, Marco
AU - Schramm, Christoph
AU - European Association For The Study Of The Liver
N1 - Currently e-pub (18th April).
PY - 2017/4/18
Y1 - 2017/4/18
N2 - Primary biliary cholangitis (PBC) is a chronic inflammatory autoimmune cholestatic liver disease, which when untreated will culminate in end-stage biliary cirrhosis. Diagnosis is usually based on the presence of serum liver tests indicative of a cholestatic hepatitis in association with circulating antimitochondrial antibodies. Patient presentation and course can be diverse and risk stratification is important to ensure all patients receive a personalised approach to their care. The goals of treatment and management are the prevention of end-stage liver disease, and the amelioration of associated symptoms. Pharmacologic approaches in practice, to reduce the impact of the progressive nature of disease, currently include licensed therapies (ursodeoxycholic acid and obeticholic acid) and off-label therapies (fibric acid derivatives, budesonide). These clinical practice guidelines summarise the evidence for the importance of a structured, life-long and individualised, approach to the care of patients with PBC, providing a framework to help clinicians diagnose and effectively manage patients.
AB - Primary biliary cholangitis (PBC) is a chronic inflammatory autoimmune cholestatic liver disease, which when untreated will culminate in end-stage biliary cirrhosis. Diagnosis is usually based on the presence of serum liver tests indicative of a cholestatic hepatitis in association with circulating antimitochondrial antibodies. Patient presentation and course can be diverse and risk stratification is important to ensure all patients receive a personalised approach to their care. The goals of treatment and management are the prevention of end-stage liver disease, and the amelioration of associated symptoms. Pharmacologic approaches in practice, to reduce the impact of the progressive nature of disease, currently include licensed therapies (ursodeoxycholic acid and obeticholic acid) and off-label therapies (fibric acid derivatives, budesonide). These clinical practice guidelines summarise the evidence for the importance of a structured, life-long and individualised, approach to the care of patients with PBC, providing a framework to help clinicians diagnose and effectively manage patients.
KW - Care pathway
KW - Liver
KW - Guidelines
KW - Cholestasis
U2 - 10.1016/j.jhep.2017.03.022
DO - 10.1016/j.jhep.2017.03.022
M3 - Article
C2 - 28427765
SN - 0168-8278
JO - Journal of Hepatology
JF - Journal of Hepatology
ER -